CapsoVision (NASDAQ:CV) Issues Earnings Results

Key Points

• CapsoVision reported a quarterly loss of ($2.02) earnings per share (EPS), significantly missing analysts' expectations of ($0.11).
• The company generated $3.32 million in revenue for the quarter, exceeding the expected $3.20 million.
• Following the earnings report, CapsoVision's stock decreased by 4.2% and traded at $3.85 on Friday.

CapsoVision (NASDAQ:CV - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($2.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($1.91), Zacks reports. The business had revenue of $3.32 million during the quarter, compared to analysts' expectations of $3.20 million.

CapsoVision Stock Down 4.2%

Shares of NASDAQ:CV traded down $0.17 during midday trading on Friday, hitting $3.85. The company's stock had a trading volume of 28,653 shares, compared to its average volume of 63,420. CapsoVision has a fifty-two week low of $3.49 and a fifty-two week high of $5.72.

Wall Street Analysts Forecast Growth

CV has been the subject of several research reports. Wall Street Zen raised CapsoVision to a "hold" rating in a research note on Sunday, July 13th. Roth Capital set a $6.00 price objective on CapsoVision and gave the stock a "buy" rating in a research note on Monday, July 28th. Finally, Benchmark initiated coverage on CapsoVision in a research note on Monday, July 28th. They set a "speculative buy" rating and a $5.00 price objective for the company.

CapsoVision Company Profile

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.